Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of April 2025. The report serves as a notification to the market regarding the Company's issued share capital and total voting rights as of March 31, 2025, in conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing does not provide financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure and voting rights.
| Metric | Value |
|---|---|
| Issued Share Capital (as of March 31, 2025) | 4,315,221,732 Ordinary Shares (31.5 pence each) |
| Treasury Shares | 187,307,190 |
| Total Voting Rights | 4,127,914,542 |
Material Changes
The filing text does not provide comparative data against a prior period to identify material changes in share capital or voting rights.
Guidance, Outlook, and Risks
The document contains no management commentary, financial guidance, outlook, risk factors, contingencies, or unusual items. It is a statutory notification intended to assist shareholders in calculating their notification thresholds under FCA rules.
Investor Verification Checklist
- Verify the total number of voting rights (4,127,914,542) against internal holdings to determine if a notification under FCA rules is required.
- Confirm the number of shares held in Treasury (187,307,190) to ensure accurate calculation of the denominator for ownership percentage.
- Check the Company Secretary contact (company.secretary@gsk.com) for submitting any required notifications.